Hyoxizone ointment, 15 g per tube

In stock: 2
$43.20

Ingredients

Active ingredients: hydrocortisone, oxytetracycline;

1 g of ointment contains: 10 mg hydrocortisone acetate, 30 mg oxytetracycline hydrochloride;

Excipients: methyl parahydroxybenzoate (E 218), mineral oil, soft yellow paraffin.

Dosage Form

Ointment.

Main physical and chemical properties: yellow ointment.

Pharmacotherapeutic group

Low-potency corticosteroids in combination with antibiotics. Hydrocortisone and antibiotics.

ATC code D07C A01.

Pharmacological properties

Pharmacodynamics.

The drug Gioxizon has a combined effect.

Oxytetracycline is an antibiotic of the tetracycline group; its mechanism of action involves the inhibition of protein synthesis in microorganisms. The drug exerts a bacteriostatic effect on both Gram-positive and Gram-negative bacteria.

Hydrocortisone acetate belongs to the group of corticosteroids with moderate local anti-inflammatory, antipruritic, and vasoconstrictive effects.

Pharmacokinetics.

When applied topically in small amounts, oxytetracycline penetrates into the systemic circulation.

When applied topically, especially to small areas of skin, hydrocortisone acetate is absorbed through the skin, metabolized to hydrocortisone and other metabolites directly in the epidermis, and only a small portion is subsequently metabolized in the liver.

Metabolites and a small portion of unchanged hydrocortisone acetate are excreted in the urine or bile.

Indications

Treatment of dermatoses complicated by infection (dry forms and scaling areas); primary allergic dermatoses, various forms of eczema, prurigo, contact and seborrheic dermatitis, and chronic psoriasis.

Contraindications

Skin lesions caused by bacterial infections (e.g., pyoderma, syphilitic lesions), viral infections (e.g., herpes zoster, common warts, flat warts, genital warts, molluscum contagiosum); infections caused by fungi and yeasts; parasitic infections (e.g., scabies); ulcerative skin lesions; ichthyosis, juvenile plantar dermatosis, acne vulgaris, rosacea, fragile capillaries, skin atrophy; skin neoplasms.

Allergy to corticosteroids, oxytetracycline hydrochloride, or other components of the medication. Not recommended for use in cases of common acne and rosacea, perioral dermatitis (dermatitis perioralis), or following preventive vaccinations. Do not apply to wounds, precancerous skin conditions, or skin cancer. Contraindicated in cases of bacterial infections (including tuberculosis) and viral infections (including herpes and chickenpox).

Special Safety Precautions

Treatment should be discontinued if symptoms of skin irritation appear.

If no improvement is observed after 7 days of use, treatment should be discontinued because hydrocortisone may mask the symptoms of a developing infection.

Do not use continuously for more than 2 weeks. Prolonged use may lead to the development of bacterial resistance to oxytetracycline hydrochloride and mitotic superinfection.

Avoid contact of the medication with the eyes, mucous membranes, and wounds.

Do not apply around the eyes due to the risk of glaucoma or cataracts.

The skin of the face and scalp, as well as the genitals, is particularly susceptible to adverse reactions. If used improperly, or in the presence of bacterial, parasitic, fungal, or viral infections, the symptoms of these conditions may be masked and/or exacerbated. Apply to the facial skin and the inguinal region only when absolutely necessary, as increased absorption and a high risk of side effects (telangiectasia, perioral dermatitis) are possible even after short-term use. Use the medication with caution in cases of subcutaneous tissue atrophy, particularly in elderly patients.

Since corticosteroids can penetrate the skin, prolonged use and application to large areas of skin should be avoided. Do not apply the medication under an occlusive dressing due to the risk of epidermal atrophy, skin stretching, and superinfection. Corticosteroids are associated with systemic side effects and hypothalamic-pituitary-adrenal dysfunction, including hyperglycemia in Cushing’s syndrome and glucosuria.

Due to its corticosteroid content, the drug should be used with caution in patients with psoriasis.

The drug contains methyl parahydroxybenzoate (E 218), which may cause allergic reactions (possibly delayed).

Interactions with Other Medications and Other Types of Interactions

No interactions have been observed when used topically as directed at the recommended doses.

It is not recommended to use two or more topical medications simultaneously due to possible changes in the concentration of active ingredients at the application site or skin redness.

During treatment with the ointment, vaccination against smallpox or other types of immunization is not recommended.

Special Considerations for Use

Use during pregnancy or breastfeeding.

This medication is contraindicated during pregnancy and breastfeeding.

Effect on reaction time when driving or operating machinery.

This medication does not impair mental or motor function, nor does it affect the ability to drive or operate machinery.

Directions for Use and Dosage

This medication is intended for topical use. Apply a thin layer of the ointment to dry, affected skin and flaky areas 2–3 times daily. Do not apply the ointment under an occlusive dressing. Treatment is usually carried out for 1–2 weeks. Do not apply to the facial skin for more than 1 week. It is recommended to use no more than 10 g of ointment per week.

Children.

Do not use this medication in children.

Overdose

With prolonged use on large areas of skin, in high doses, or when applied under an occlusive dressing, symptoms of overdose may occur, manifested by an increase in systemic side effects characteristic of corticosteroids (hyperglycemia, glucosuria, Cushing’s syndrome) or for oxytetracycline. In case of overdose, discontinue use of the drug gradually.

Side Effects

Skin and subcutaneous tissue:

  • local skin irritation, rash, burning sensation, itching, heat rash, dry skin;
  • hypertrichosis, skin discoloration or depigmentation;
  • contact dermatitis, eczema, delayed wound healing, redness, striae, steroid purpura, skin discoloration, skin maceration, acne-like lesions;
  • perioral dermatitis, with or without skin atrophy, impaired epidermal growth, and subcutaneous tissue atrophy;
  • inflammation of hair follicles, development of secondary bacterial or fungal infections;
  • “rebound effect,” which may lead to steroid dependence;
  • telangiectasia.

Endocrine system: adrenocortical suppression, hyperglycemia, glucosuria.

Systemic disorders occur due to the absorption of hydrocortisone acetate into the systemic circulation and cause:

  • Cushing’s syndrome, intracranial hypertension;
  • angioedema;
  • increased resistance of bacterial strains;
  • blastomycosis.

Ocular effects: increased intraocular pressure and risk of cataracts (if the drug comes into regular contact with the conjunctiva).

Immune system: allergic reactions, hypersensitivity reactions, including angioedema and photosensitivity.

Shelf life

3 years.

Storage conditions

Store in the original packaging at a temperature not exceeding 25 °C.

Keep out of reach of children.

Packaging

15 g of ointment in a No. 1 tube in a cardboard package.

Dispensing Category

By prescription.